High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis.

Abstract

Serum neurofilament light chain (sNfL) is a promising biomarker of neuroaxonal damage in persons with multiple sclerosis (pwMS). In cross-sectional studies, sNfL has been associated with disease activity and brain magnetic resonance imaging (MRI) changes; however, it is still unclear to what extent in particular high sNfL levels impact on subsequent disease evolution. sNfL was quantified by an ultrasensitive single molecule array (Simoa) in 199 pwMS (median age=34.2 years, 64.3% female) and 49 controls. All pwMS underwent 3-T MRI to assess global and compartmental normalized brain volumes, T2-lesion load, and cortical mean thickness. Follow-up data and serum samples were available in 144 pwMS (median follow-up time=3.8 years). Linear and binary logistic models were used to estimate the independent contribution of sNfL for changes in MRI and Expanded Disability Status Scale (EDSS). Age-corrected sNfL z-scores from a normative database of healthy controls were used for sensitivity analyses. High sNfL levels at baseline were associated with atrophy measures of the whole brain (standardized beta coefficient βj= -0.352, p< 0.001), white matter (βj= -0.229, p= 0.007), thalamus (βj= -0.372, p= 0.004), and putamen (βj= -1.687, p= 0.012). pwMS with high levels of sNfL at baseline and follow-up had a greater risk of EDSS worsening (p= 0.007). Already single time point elevation of sNfL has a distinct effect on brain volume changes over a short-term period, and repeated high levels of sNfL indicate accumulating physical disability. Serial assessment of sNfL may provide added value in the clinical management of pwMS.